Rosumop 20 mg - 14 F.C. Tablet

-Heterozygous familial hypercholesterolemia: High-intensity therapy: Oral: Initial: 20 or 40 mg once daily; if 20 mg once daily is initiated and tolerated, increase to 40 mg once daily. -Homozygous familial hypercholesterolemia: High-intensity therapy: Oral: 40 mg once daily. -Prevention of atherosclerotic cardiovascular disease: Primary prevention: 1-Patients without diabetes, 40 to 75 years of age, and with LDL-C 70 to 189 mg/dL: a-In case of patients with ASCVD 10-year risk = 5% to <7.5%: Moderate-intensity therapy: Oral: 5 to 10 mg once daily to reduce LDL-C by 30% to 49%. b-In case of patients with ASCVD 10-year risk ≥7.5% to <20%: Moderate-intensity therapy: Oral: 5 to 10 mg once daily to reduce LDL-C by 30% to 49%. c-In case of patients with ASCVD 10-year risk ≥20%: High-intensity therapy: Oral: 20 to 40 mg once daily to reduce LDL-C by ≥50%. 2-Patients with diabetes: a-In case of patients 40 to 75 years of age without additional ASCVD risk factors: Moderate-intensity therapy: Oral: 5 to 10 mg once daily to reduce LDL-C by 30% to 49%. b-In case of patients with ASCVD risk ≥20% or multiple ASCVD risk factors: High-intensity therapy: Oral: 20 to 40 mg once daily to reduce LDL-C by ≥50%. 3-Patients with LDL-C ≥190 mg/dL and 20 to 75 years of age: High-intensity therapy is indicated regardless of ASCVD risk calculation or coexisting diabetes mellitus: High-intensity therapy: Oral: 20 to 40 mg once daily to reduce LDL-C by ≥50%. Secondary prevention in patients with established ASCVD (eg, coronary heart disease, cerebrovascular disease, peripheral arterial disease): High-intensity therapy: Oral: 20 to 40 mg once daily to reduce LDL-C by ≥50%. -Pediatric dosing: see dosage and administration.